ERBB2 and melanoma: The most recent versions of the prognostic scoring systems have also now integrated tumor biology and molecular profiles, such as EGFR and ALK alterations in NSCLC adenocarcinoma (Lung-molGPA) [21], estrogen/progesterone and HER2-receptor status for breast cancer (Breast-GPA) [19], and BRAF status in melanoma (Melanoma-molGPA) [20] to more accurately estimate a modern BM patient’s outcome.